Immunotherapy for ovarian cancer.
Bookman
M A
MA
Fox Chase Cancer Center, Philadelphia, Pennsylvania.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy; D016207:Cytokines / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy; D016219:Immunotherapy, Adoptive; D000922:Immunotoxins / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use; D051379:Mice; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D016207:Cytokines; D007155:Immunologic Factors; D000922:Immunotoxins; D007376:Interleukin-2; D007457:Iodine Radioisotopes